Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nereus Pharmaceuticals, a drug discovery and development company, has announced that it is conducting a randomized Phase II clinical trial evaluating the vascular disrupting agent NPI-2358 in combination with standard chemotherapy in patients with non-small cell lung cancer.
Subscribe to our email newsletter
This study follows on positive outcomes in the Phase I study assessing the safety, pharmacokinetics and efficacy of the combination.
The Phase II Advance trial will assess NPI-2358 in combination with docetaxel compared to docetaxel alone in patients with non-small cell lung cancer who previously failed at least one chemotherapy regimen.
Overall survival will be the primary endpoint of the trial, and progression free survival and tumor response rates will be compared as secondary endpoints. Approximately 150 patients will participate in the trial at clinical trial sites in the US, Australia, India, and South America.
Nereus is also evaluating NPI-2358 in other solid tumor indications and expects to initiate additional Phase II studies in 2009.
Matthew Spear, chief medical officer of Nereus, said: “The development program for NPI-2358 has consistently exceeded our expectations. The Advance study provides a unique opportunity to assess the efficacy of NPI-2358 in a group of patients that could direly use a treatment that improves the outcomes of current chemotherapy regimens.”